Published in Haematologica on March 01, 2005
A testing framework for identifying susceptibility genes in the presence of epistasis. Am J Hum Genet (2005) 3.69
An ensemble learning approach jointly modeling main and interaction effects in genetic association studies. Genet Epidemiol (2008) 1.17
Genome-wide association reveals three SNPs associated with sporadic amyotrophic lateral sclerosis through a two-locus analysis. BMC Med Genet (2009) 0.80
Identification of interacting genes in genome-wide association studies using a model-based two-stage approach. Ann Hum Genet (2010) 0.75
Factor XIII-A Val34Leu polymorphism might beassociated with myocardial infarction risk: an updated meta-analysis. Int J Clin Exp Med (2014) 0.75
Multiple thrombophilia mutations as a possible cause of premature myocardial infarction. Wien Klin Wochenschr (2017) 0.75
Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2007) 2.95
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol (2005) 2.47
Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol (2012) 2.32
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv (2012) 2.07
New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. Rev Esp Cardiol (Engl Ed) (2011) 2.01
Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol (2008) 1.89
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun (2012) 1.67
Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica (2009) 1.65
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica (2008) 1.62
Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol (2008) 1.57
Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost (2015) 1.49
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed) (2011) 1.46
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg (2006) 1.45
[Annexin V levels in survivors of early myocardial infarction]. Rev Esp Cardiol (2002) 1.44
Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting. Thromb Haemost (2011) 1.43
[Minimum salvaged myocardium after rescue percutaneous coronary intervention: quantification by cardiac magnetic resonance]. Rev Esp Cardiol (2011) 1.42
Does pacemaker implantation provide long-term benefits in severe obstructive hypertrophic cardiomyopathy? Rev Esp Cardiol (2009) 1.41
Pro: "Antidote for new anticoagulants"--specific target of inhibition requires a specific target for neutralisation. Thromb Haemost (2012) 1.41
[Plasma concentration of big endothelin-1 and its relation with plasma NT-proBNP and ventricular function in heart failure patients]. Rev Esp Cardiol (2005) 1.38
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood (2010) 1.29
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost (2009) 1.21
Coronary aneurysms after drug-eluting stents implantation. Eur Heart J (2007) 1.16
Premature myocardial infarction: clinical profile and angiographic findings. Int J Cardiol (2007) 1.15
Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost (2003) 1.15
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol (2012) 1.14
[Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev Esp Cardiol (2007) 1.13
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
[Effect of the early administration of pravastatin on C-reactive protein and interleukin-6 levels in the acute phase of myocardial infarction with ST segment elevation]. Rev Esp Cardiol (2004) 1.08
Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thromb Res (2010) 1.08
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood (2009) 1.04
Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr Cancer (2004) 1.03
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol (2006) 1.03
Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings. Transfus Apher Sci (2007) 1.02
Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol (2013) 1.02
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost (2013) 1.02
Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke (2004) 1.01
Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther (2015) 1.00
Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol (2011) 0.99
Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J (2003) 0.98
Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models. Am J Pathol (2005) 0.98
Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes. Atherosclerosis (2013) 0.97
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke (2006) 0.95
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J (2007) 0.95
Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J (2008) 0.95
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood (2006) 0.94
Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J (2009) 0.94
Thrombosis as a conformational disease. Haematologica (2005) 0.93
Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica (2011) 0.93
Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail (2010) 0.93
Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood (2007) 0.92
Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med (2011) 0.92
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res (2008) 0.92
Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism. Blood (2012) 0.92
Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol (2007) 0.92